Endpoints News
FDA gives Denali accelerated approval for rare disease drug
The FDA granted accelerated approval to Denali Therapeutics’ rare disease drug Avlayah, bucking a recent trend of rejections in the space that has put the agency under political pressure.
Avlayah, whose generic name is tividenofusp …